$BCLI

BRAINSTORM CELL THERAPEUTICS INC.

CIK:0001137883|SEC Filings

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development, net	$ 963	$ 1,120	$ 1,725	$ 2,424
General and administrative	2,650	1,453	3,934	3,238
Operating loss	(3,613)	(2,573)	(5,659)	(5,662)
Financial income (expense), net	(242)	(330)	(323)	(284)
Gain (loss) on change in fair value of Warrants liability				179
Net loss	$ (3,855)	$ (2,903)	$ (5,982)	$ (5,767)
Basic net loss per share from continuing operations (in dollars per share)	$ (0.35)	$ (0.34)	$ (0.54)	$ (0.77)
Diluted net loss per share from continuing operations (in dollars per share)	$ (0.35)	$ (0.34)	$ (0.54)	$ (0.77)
Weighted average number of shares outstanding used in computing basic net loss per share (in shares)	11,034,775	8,620,400	11,034,775	7,487,495
Weighted average number of shares outstanding used in computing diluted net loss per share (in shares)	11,034,775	8,620,400	11,034,775	7,487,495

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2026

Jun. 30, 2025

Jun. 30, 2026

Jun. 30, 2025

Cash flows from operating activities:

Net loss

$ (3,855)

$ (2,903)

$ (5,982)

$ (5,767)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation

103

Stock-based compensation related to options granted to employees and directors

2,244

503

2,377

1,220

Change in operating lease liability

Decrease in other accounts receivable and prepaid expenses

(127)

(5)

(18)

(495)

Increase in accounts payable

171

(800)

421

(83)

Increase in interest expense

139

Loss (gain) on change in fair value of warrants (Note 4)

(179)

Increase (decrease) in employees related liability and accrued expenses

564

(412)

758

Net cash used in operating activities

(895)

(3,502)

(2,215)

(5,133)

Cash flows from financing activities:

Proceeds from issuance of shares in at-the-market (ATM) offering (Note 4)

^[1]

3,350

4,035

Proceeds from Issuance of shares for private placement (Note 4)

^[1]

1,023

1,993

Proceeds from short-term loans (Note 6)

(125)

(1,099)

155

(199)

Debt-for-Equity Swap

450

Proceeds from warrants issuance (Note 4)

^[1]

1,501

Net cash provided by financing activities

898

2,701

2,148

5,787

Increase (decrease) in cash and cash equivalents

(801)

(67)

654

Cash, cash equivalents and restricted cash at the beginning of the period

206

1,826

276

371

Cash, cash equivalents and restricted cash at end of the period

$ 209

$ 1,025

$ 209

1,025

Non-Cash Activities:

Reclassifying the warrants liabilities to equity (Note 4)

$ 268

[1]	Presented after neutralizing costs of issuance.

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current Assets:
Cash and cash equivalents	$ 22	$ 29
Other accounts receivable	162	86
Prepaid expenses and other current assets	132	192
Total current assets	316	307
Long-Term Assets:
Prepaid expenses and other long-term assets	27	25
Restricted Cash	187	247
Right of use asset (Note 3)	106	208
Property and equipment, net	152	235
Total Long-Term Assets	472	715
Total assets	788	1,022
Current Liabilities:
Accounts payable	7,488	7,067
Accrued expenses	454	396
Short-term loans (Note 6)	1,261	967
Operating lease liability (Note 3)	113	208
Employees related liability	3,069	2,369
Total current liabilities	12,385	11,007
Total liabilities	12,385	11,007
Stockholders' Deficit:
Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstanding	16	16
Additional paid-in-capital	231,428	227,058
Treasury stock	(116)	(116)
Accumulated deficit	(242,925)	(236,943)
Total stockholders' deficit	(11,597)	(9,985)
Total liabilities and stockholders' deficit	$ 788	$ 1,022